Group 1 - The core viewpoint of the article highlights that Xianruida Medical-B (06669) has seen a nearly 5% increase in stock price following the announcement of a strategic partnership with Boston Scientific [1] - The collaboration includes a total cooperation agreement and a total service agreement, aimed at deepening the strategic partnership established in 2023 [1] - Over the next three years, Boston Scientific is set to purchase Xianruida's products for global sales, with a transaction cap of $170 million [1]

消息面上，先瑞达与波士顿科学旗下公司签署了总合作协议及总服务协议。这是继2023年首次签约后， 双方将继续深化战略合作，延续并拓展此前的成功伙伴关系，共同协定未来三年内，双方在产品全球商 业化、产品制造服务、产品研发等领域开展的一系列合作。其中，在销售层面，未来三年波士顿科学采 购先瑞达产品用于全球销售的交易金额上限合计1.7亿美元。 先瑞达医疗-B(06669)午后涨近5%，截至发稿，涨4.36%，报13.17港元，成交额304.16万港元。 ...

Group 1 - A-shares and Hong Kong stocks experienced a significant rebound, with the Shanghai Composite Index rising by 1.19% and the Hang Seng Index increasing by 0.92% [1] - The largest medical ETF in the market (512170) and the only drug ETF (562050) both rose over 1%, indicating a broad recovery in the medical sector [1] - The medical ETF (512170) showed a strong technical signal with a "bullish engulfing" pattern, suggesting a potential trend reversal [1] Group 2 - The pharmaceutical sector in A-shares also saw a surge, with the drug ETF (562050) rising by 1.19%, driven by contributions from innovative and traditional Chinese medicine stocks [3] - The drug ETF (562050) has approximately 25% weight in traditional Chinese medicine, which helps mitigate the volatility of the overall pharmaceutical index [3] Group 3 - The Hong Kong innovation drug sector is showing signs of recovery, with the Hong Kong innovation drug ETF (520880) successfully closing in the green, attracting "bottom-fishing" funds [5] - The fund size of the Hong Kong innovation drug ETF (520880) reached a new high of 4.172 billion shares, reflecting strong investor interest [5] Group 4 - The A+H pharmaceutical sector has been in a correction phase for three months, and analysts suggest that this may be an opportune time for medium to long-term investments in pharmaceutical assets [8] - Recent positive developments in the pharmaceutical industry include overseas collaborations and increasing demand for CXO services, indicating a favorable outlook for the sector [9] Group 5 - The fund manager of the Hong Kong innovation drug ETF (520880) maintains a balanced allocation strategy, highlighting the potential for recovery in the innovative drug industry and related sectors [10] - New investment tools, such as the Hong Kong medical ETF (159137), are being launched to track the medical innovation theme, covering various core leaders in the medical field [7]

Acotec Scientific Holdings Limited 先瑞達醫療科技控股有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock Code 股份代號 : 6669) N O T I F I C AT I O N L E T T E R Dear non-registered shareholder(s), 17 December 2025 Acotec Scientific Holdings Limited (the "Company") – Notice of Publication of Circular for Extraordinary General Meeting (the "Current Corporate Communications") The Current Corporate Communications of the Company have been published in English and Chinese languages and ar ...

Acotec Scientific Holdings Limited 先瑞達醫療科技控股有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock Code 股份代號 : 6669) N O T I F I C AT I O N L E T T E R 17 December 2025 Dear registered shareholders, Acotec Scientific Holdings Limited (the "Company") – Notice of Publication of Circular for Extraordinary General Meeting and Form of proxy (the "Current Corporate Communications") The Current Corporate Communications of the Company have been published in English and Chinese lang ...

本人╱吾等 （附註1） Acotec Scientific Holdings Limited 先瑞達醫療科技控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6669） 於2025年12月31日（星期三）舉行的股東特別大會代表委任表格 地址為 為上述名稱的公司已發行股本中每股面值0.00001美元的股份 的登記持有人，現委任股東特別大會主席或 （附註3） 附註： 個人資料收集聲明 （附註2） 股 1. 請用正楷填上全名及地址。 2. 請填上本代表委任表格所涉以 閣下的名義登記的股份數目。如未填上股份數目，本代表委任表格將被視為 閣下名下所有本公司股份的委任表格。 3. 如擬委派股東特別大會主席以外的人士為代表，請將「股東特別大會主席或」字樣刪去，並在空欄內填上擬委派代表的姓名及地址。本代表委任表格的 每項更改，均須由簽署人簡簽示可。 4. 注意：倘 閣下欲投票贊成決議案，請在「贊成」欄內填上「✓」號，倘 閣下欲投票反對決議案，則請在「反對」欄內填上「✓」號。倘未有填上任何「✓」 號，則 閣下的受委代表可酌情自行投票表決。 閣下的受委代表亦有權就於大會上提呈的決議案的任何修訂酌情自行投票表決。 5. ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示，概不就因本通告全部或任何部分內容所產生或因依賴該等內容而引致的任 何損失承擔任何責任。 Acotec Scientific Holdings Limited 先瑞達醫療科技控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6669） 股東特別大會通告 茲通告本公司將於2025年12月31日（星期三）上午十時正假座中國北京北京經濟 技術開發區隆慶街10號寫字樓8層Dhalia會議室就下列事項舉行股東特別大會（「股東特 別大會」）： 董事會主席、執行董事兼行政總裁 李靜 謹啟 香港，2025年12月17日 – 1 – 普通決議案 承董事會命 先瑞達醫療科技控股有限公司 1. 「動議： (A) 批准、追認及確認本公司與BSG所訂立日期為2025年12月12日的 2026年總合作協議（註有「A」字樣的副本已呈交大會，並由大會主席 簡簽以資識別）、其條款以及其項下擬進行的非豁免持續關連交易（包 括建議年度上限）； (B) 批准、追認及確認本公司與BSG所訂立日期為2025年12月12日的 ...

此乃要件 請即處理 閣下如對本通函或應採取的行動有任何疑問，應諮詢 閣下的股票經紀、銀行經理、律師、專業會計師或 其他專業顧問。 閣下如已售出或轉讓名下所有先瑞達醫療科技控股有限公司的股份，應立即將本通函送交買主或承讓人， 或經手買賣的銀行、股票經紀或其他代理商，以便轉交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示概不就因本通函全部或任何部分內容而產生或因倚賴該等內容而引致的任何 損失承擔任何責任。 Acotec Scientific Holdings Limited 先瑞達醫療科技控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6669） 持續關連交易 及 股東特別大會通告 獨立董事委員會及獨立股東的 獨立財務顧問 本公司將按原定計劃於2025年12月31日（星期三）上午十時正假座中國北京北京經濟技術開發區隆慶街10 號寫字樓8層Dhalia會議室召開股東特別大會，其通告載於本通函第69至70頁。本通函隨附股東特別大會 適用的代表委任表格。該代表委任表格亦刊載於香港聯合交易所有限公司網站( www.hke ...

Group 1 - The average annual salary for CFOs in Hong Kong is 1.602 million RMB, while in mainland China it is 857,600 RMB, indicating that Hong Kong CFOs earn approximately 1.6 to 1.9 times more than their mainland counterparts [1][2] - In Hong Kong, 5.34% of CFOs earn over 5 million RMB annually, while nearly a quarter of mainland CFOs earn over 1 million RMB [1] - The salary structure in both markets shows a "high middle + high salary tail" pattern, with top-tier CFOs in leading companies earning several million or even tens of millions [1] Group 2 - Individual characteristics significantly influence CFO salaries, with male CFOs earning more than female CFOs in both markets, although top female CFOs demonstrate competitive salaries [1][2] - The age group of 40-55 years is the primary demographic for CFOs, with salaries increasing with age and experience; in Hong Kong, CFOs over 60 earn an average of 2.4563 million RMB [1][2] - Educational background and overseas experience are also linked to salary levels, with PhD CFOs in mainland China earning an average of 1.3004 million RMB, and those with overseas experience earning 556,000 RMB more than their counterparts without [1][2] Group 3 - Industry and company characteristics are key factors affecting CFO salaries; in Hong Kong, the "new economy + domestic demand" sectors (TMT, consumer, healthcare) lead in salary levels, with a median of around 1.2 million RMB [2] - In mainland China, the financial and real estate sectors offer the highest average salaries at 1.2241 million RMB, followed by healthcare and high-tech industries [2] - Company size and profitability are directly correlated with CFO salaries; companies with higher ROE see significant salary premiums, with CFOs in firms with ROE over 20% earning an average of 1.605 million RMB [2] Group 4 - The average salary for CFOs in AH-listed companies is 3.05 million RMB, reflecting a 15% increase from 2023, with leading companies showing a "high base + double-digit growth" trend [2] - The overall salary growth is expected to moderate, but the premium for top-tier CFOs and structural differentiation will continue; salary structures are shifting towards long-term incentives linked to ROE and cash flow [2] - The increasing importance of digital and AI capabilities is becoming a significant source of salary premiums, with the CFO role evolving into a strategic leader [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 獨立董事委員會及獨立股東的 獨立財務顧問 持續關連交易 Acotec Scientific Holdings Limited 先瑞達醫療科技控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6669） 持續關連交易 於本公告日期，BSG為本公司的控股股東，持有本公司已發行股本65.0%權益。 因此，BSG為本公司於上市規則項下的關連人士，根據上市規則第14A章， 2026年框架協議項下擬進行的交易構成本公司的持續關連交易。 由於各份2026年框架協議項下交易的建議年度上限之最高適用百分比率超過 5%，各份2026年框架協議項下交易須遵守上市規則第14A章項下的申報、公 告、年度審閱及獨立股東批准規定。 2026年總合作協議 於2023年7月20日，本公司與BSG訂立2023年總合作協議，以規管訂約方就商 業化若干先瑞達產品所進行的合作，年期為2023年7月20日至2025年12月31 日。根據 ...